Posted by Michael Wonder on 16 Jan 2022
Glenmark receives NDA approval by the United States FDA for Ryaltris nasal spray for the treatment of symptoms of seasonal allergic rhinitis in adults and paediatric patients 12 years of age and older
14 January 2022 - Ryaltris will be marketed and distributed in the United States through its partner Hikma.
Glenmark Pharmaceuticals announced that has received FDA approval on its new drug application for Ryaltris, an innovative, fixed-dose (metered), prescription, combination drug product nasal spray for the treatment of symptoms of seasonal allergic rhinitis in adults and paediatric patients 12 years of age and older in the United States.
